Context Therapeutics Inc. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Context Therapeutics disclosed interim Phase 1a clinical data for CTIM-76 (claudin-6 x CD3 bispecific T cell engager) in heavily pretreated platinum-resistant ovarian cancer (PROC) patients as of May 29, 2026. In 9 RECIST-evaluable PROC patients at target weekly doses (140–280 μg), CTIM-76 showed 29% confirmed ORR, 57% disease control rate, low cytokine release syndrome (11% Grade 1, 0% Grade ≥2), and durable responses (66% still on therapy). The company also presented preclinical/early-stage data for CT-202 (nectin-4 x CD3), designed with pH-dependent conditional activation to reduce skin toxicity. CTIM-76 has FDA Fast Track Designation; Phase 1b in PROC is planned for Q1 2027 initiation with Q2 2027 initial Q3W dosing data expected.
Why this rating
Early-stage clinical efficacy and safety data are encouraging for a ~$58M biotech, supporting advancement of lead program. However, data set is small (n=9), early-stage, and efficacy signal must be validated in larger cohorts. Moderate significance: validates target and mechanism but leaves substantial execution risk.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.